What is Gliknik?
Gliknik is a biotechnology enterprise dedicated to the discovery and development of novel biologics designed to address unmet medical needs in patients with immune disorders. The company's core competency lies in its sophisticated approach to immune system modulation, which serves as the foundation for its diverse drug candidate portfolio, including GL-2045 and GL-0719. These assets are currently being evaluated for their efficacy in treating challenging conditions such as immune thrombocytopenia and Cold Agglutinin Disease. By leveraging a multidisciplinary team of scientists and a global network of clinical experts, Gliknik is effectively bridging the gap between fundamental immunological research and practical, life-saving therapeutic applications.
How much funding has Gliknik raised?
Gliknik has raised a total of $52M across 11 funding rounds:
Series A
$2.9M
Unspecified
$2.4M
Unspecified
$849K
Unspecified
$3.5M
Unspecified
$2M
Private Equity
$9.9M
Series B
$4.9M
Unspecified
$2.8M
Debt
$148K
Series C
$11.5M
Debt
$11M
Series A (2008): $2.9M, investors not publicly disclosed
Unspecified (2010): $2.4M, investors not publicly disclosed
Unspecified (2010): $849K, investors not publicly disclosed
Unspecified (2011): $3.5M, investors not publicly disclosed
Unspecified (2011): $2M, investors not publicly disclosed
Private Equity (2012): $9.9M, investors not publicly disclosed
Series B (2012): $4.9M led by Baxter International
Unspecified (2013): $2.8M, investors not publicly disclosed
Debt (2021): $148K featuring PPP
Series C (2021): $11.5M backed by First In Ventures and SAISO Partners
Debt (2025): $11M, investors not publicly disclosed
Key Investors in Gliknik
Baxter International
Baxter International is a global healthcare company that develops and manufactures medical devices, pharmaceuticals, and hospital care products. Its offerings include infusion systems, injectable therapies, surgical technologies, and patient monitoring solutions used by hospitals, clinics, and healthcare providers worldwide.
First In Ventures
A venture capital firm focused on identifying and supporting high-growth potential companies within the life sciences and biotechnology sectors.
SAISO Partners
An investment management group that provides strategic capital and operational guidance to emerging firms in the healthcare and pharmaceutical industries.
What's next for Gliknik?
With the recent influx of capital, Gliknik is well-positioned to advance its clinical trials and strengthen its intellectual property portfolio. The strategic focus will likely shift toward scaling manufacturing processes and optimizing the regulatory pathway for its lead candidates. As the company navigates the complexities of late-stage drug development, the emphasis will remain on demonstrating clinical superiority and safety in its target patient populations. Future milestones will be critical in determining the company's long-term viability and potential for commercialization, as it continues to refine its therapeutic platform to meet the evolving demands of the global healthcare market.
See full Gliknik company page
